LPL Financial LLC cut its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 5.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,579 shares of the insurance provider's stock after selling 2,061 shares during the period. LPL Financial LLC's holdings in Humana were worth $8,266,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Pinnacle Wealth Management Advisory Group LLC boosted its holdings in shares of Humana by 3.6% in the fourth quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider's stock valued at $272,000 after acquiring an additional 37 shares in the last quarter. Atlas Brown Inc. boosted its stake in Humana by 0.6% during the 4th quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider's stock valued at $1,611,000 after purchasing an additional 38 shares in the last quarter. Mather Group LLC. increased its position in shares of Humana by 21.0% during the 4th quarter. Mather Group LLC. now owns 236 shares of the insurance provider's stock valued at $60,000 after purchasing an additional 41 shares during the period. Capital Advisors Ltd. LLC increased its position in shares of Humana by 26.1% during the 4th quarter. Capital Advisors Ltd. LLC now owns 208 shares of the insurance provider's stock valued at $53,000 after purchasing an additional 43 shares during the period. Finally, Retirement Planning Co of New England Inc. lifted its holdings in shares of Humana by 4.7% in the fourth quarter. Retirement Planning Co of New England Inc. now owns 966 shares of the insurance provider's stock valued at $245,000 after buying an additional 43 shares during the period. 92.38% of the stock is owned by institutional investors.
Humana Stock Up 1.9 %
Shares of NYSE HUM traded up $5.30 during mid-day trading on Thursday, reaching $290.83. The company had a trading volume of 2,006,121 shares, compared to its average volume of 1,748,409. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The stock's 50 day moving average is $265.56 and its 200-day moving average is $270.77. The stock has a market capitalization of $35.10 billion, a PE ratio of 29.23, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62.
Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, equities analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.
Humana Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.22%. Humana's dividend payout ratio (DPR) is 35.58%.
Analysts Set New Price Targets
HUM has been the topic of a number of research analyst reports. Morgan Stanley lowered their target price on Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 12th. Piper Sandler boosted their target price on shares of Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a report on Wednesday, January 15th. Barclays increased their target price on shares of Humana from $255.00 to $270.00 and gave the company an "equal weight" rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. decreased their price target on shares of Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 18th. Finally, StockNews.com upgraded Humana from a "hold" rating to a "buy" rating in a research report on Monday. Seventeen research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $284.25.
Check Out Our Latest Report on HUM
About Humana
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Read More
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
